of epilepsy (including active epilepsy and epilepsy in remission) was estimated at 3.14/1000 for age above 30 years. In comparison with prior surveys, the study also indicated that the prevalence rate of epilepsy was rather stable over the in recent two decades. 26 Concerning the mortality risk, there have been only two hospitalbased studies carried out to investigate the risk of mortality in Taiwanese patients with epilepsy. 24, 25 Due to small sample size, interpretation of cause-specific mortality risk is rather limited, and reliable mortality risk estimates for detailed age and sex stratifications were not likely. We therefore conducted this cohort study with a larger cohort of people with epilepsy recruited from a tertiary hospital in southern Taiwan. With a sufficient number of study subjects, this study aims to investigate the sex, age, and cause-specific mortality risk associated with epilepsy in Taiwan.
Results from this study were also compared with findings from other nations globally.
Subjects and methods
Between 1989 and 2008, a total of 2180 prevalent epilepsy patients, including 1214 men and 966 women, were treated at a tertiary hospital in southern Taiwan. We reviewed medical charts of those patients for their demographic characteristics and clinical manifestations of the disease. The charts included personal identification number (PIN), gender, date of birth, and date of the initial diagnosis of epilepsy. Information on seizure type and diagnosis was ascertained according to the guidelines recommended by the Commission on Epidemiology and Prognosis of the International League against Epilepsy. 27 The cohort was then linked, using PIN, to Taiwan Death Register (TDR) between 1989 and 2008. The TDR is considered accurate and complete because it is mandatory to register all deaths in Taiwan and for physicians to complete all death certificates. 28 The linkage We compared patients' risks of overall and age-and sex-specific mortality to those of the general population. We also compared the risks of mortality from various causes including malignant neoplasms (ICD codes: 140-208 & C00-C97), heart disease (ICD  code: 398, 402, 416, 425, 427-428 & I09, I11, I27, I42, I49, I50),  ischemic heart disease (ICD codes: 410-414 & I20-I25), cerebrovascular disease (ICD codes: 430-438 & I60-I69), pneumonia (ICD  codes: 480-486 & J12-J18), liver cirrhosis (ICD codes: 571 & K70,  K73-K74) , and injury (ICD code: E800-E999 & V01-Y89) between the patients with epilepsy and the general population. The expected number of death for the epileptic cohort was calculated from the person-year approach, using the age (10-year intervals) and sex-specific annual mortality rates with reference to the general population. We first calculated the number of person-years being observed for each study subject. The date of study entry was the date of initial primary or secondary diagnosis as epilepsy during the study period, i.e., 1989-2008. The date of completion of follow-up was the date of death encountered by the study subjects who died prior to the end of 2008. For those who were intact during the study period, the date of end-of-follow-up was set to be December 31, 2008 . The annual age-sex-specific population sizes for the general population during the study period were derived from the national annual household registration statistics published by Ministry of the Interior of Taiwan. Standardized mortality ratios (SMRs) were calculated as relative risk estimates. The average annual average size of the general population over the study period was 21, 769, 198 . The 95% confidence interval (CI) for SMR was estimated using the exact estimation. 29, 30 The analysis was performed using SAS (version 9.1; SAS Institute, Cary, NC), and level of significance was set at a p-value of 0.05. The National Cheng Kung University Medical School IRB has approval of this study (ER-98-065).
Results
The study cohort consisted of 1214 male subjects and 966 females. The age ranged from 0 to 82 years at the first appearance in the cooperative hospital, with a median and mean (AESD) age of 15 and 21 AE 16 years old, respectively. Over a maximum of nearly 20 years of follow-up, a total of 22,617 person-years were accumulated. The length of follow-up varied, ranging from 0 to 4 years (n = 423), 5 to 9 years (n = 601), 10 to 14 years (n = 664), and 15 years and longer (n = 492). Totally, 266 deaths (193 men and 73 women) were noted at the end of follow-up. The mean age at death was 50 years (SD = 19 years) for all 266 deceased subjects. Table 1 shows the overall and age-and sex-specific SMRs of allcause mortality. The overall SMR was significantly increased for patients with epilepsy (SMR, 2.5; 95% CI, 2.2-2.8). Both male and female patients had a very similar risk estimate. The age-specific SMR was also significantly increased in patients with epilepsy of all age groups except those aged 10-19 and 70+ years. The most elevated SMR was noted in young children epilepsy aged 0-9 (SMR, 34.0; 95% CI, 4.1-122.8) followed by those aged 20-29 years (SMR, 6.3; 95% CI, 4.4-8.7). The age-sex-specific analysis showed that the most increased SMR for male patients was noted in children patients aged 0-9 years (SMR, 51.8; 95% CI, 6.2-187.2) followed by those aged 20-29 years (SMR, 5.6; 95% CI, 3.5-8.2), while patients aged 20-29 years were at the most elevated risk of mortality (SMR, 8.6; 95% CI, 4.4-14.9) in females.
The cause-specific SMRs are shown in Table 2 . The SMR of all malignant neoplasm was significantly increased at 1.7 (95% CI, 1.2-1.7). The cancer-specific analysis further indicated a substantially and significantly increased SMR for brain tumor (SMR, 21.4; 95% CI, 9.2-23.1). We also noted a significantly increased SMR for liver cancer (2.6; 95% CI, 1.4-2.7). In addition to malignant neoplasm, heart disease (SMR, 2.6; 95% CI, 1.2-2.7), cerebrovascular disease (SMR, 2.6; 95% CI, 1.6-2.6) and pneumonia (SMR, 2.5; 95% CI, 1.1-2.7) were all significantly and positively associated with epilepsy mortality. On the other hand, we found no significant association of epilepsy with mortality from ischemic heart disease or liver cirrhosis. Patients with epilepsy were also at a significantly increased SMR for all injuries (SMR, 3.6; 95% CI, 2.7-3.6), as well as for certain injuries including transport accidents (SMR, 2.5; 95% CI, 1.4-2.6), accidental falls (SMR, 5.7; 95% CI, 2.2-6.1), accidental drowning (SMR, 8.8; 95% CI, 3.5-9.6), and suicide (SMR, 4.0; 95% CI, 2.4-4.1).
Discussion

Main findings
In 22,617 person-years observed over nearly 20 years, we noted an SMR of 2.5 for all-cause mortality in our sample patients, with a slightly higher risk estimate for men (SMR = 2.6) than for women (SMR = 2.2). In the age-specific analysis, our study noted a remarkably increased risk of mortality in younger patients with epilepsy. Like findings from the studies of many developed nations, our study also noted that Taiwanese people with epilepsy were also at significantly elevated risk of mortality from non-injury causes including malignant neoplasm (especially form brain tumor), cerebrovascular disease, pneumonia, and suicide, with an SMR ranging from 1.7 for malignant neoplasm (21.4 for brain tumor) to 2.6 for cerebrovascular disease. Additionally, SMRs for certain injury related causes, such as drowning (8.8) and fall (5.7)
were substantially high in patients with epilepsy. Our results also provided support for an increased risk of mortality from suicide and transport accidents in patients with epilepsy, with an SMR of 4.0 and 2.5, respectively. Given that the SMRs for allcause mortality ranged from 1.6 to 5.3 in most previous community-based studies, and tended to be higher in studies of selected population (3.2-7.9), 12 the patients with epilepsy in southern Taiwan experienced essentially the same magnitude of increased risk of mortality, as compared to the general Taiwanese population.
Age and sex-specific SMR
Although highest in the younger patients, the SMR was significantly increased in all age groups before 70 years. Like many previous studies, 7,13 our study also found an inverse relation between SMR and age. The highest SMRs were found in children, while decreasing SMRs were found with increasing age. A recent study reported that childhood-onset epilepsy was associated with a substantially higher risk of epilepsy-related death, including sudden and unexplained death. 31 The study by Sillanpä ä et al. also
noted that younger patients with epilepsy had a greater risk of mortality from suicide. 31 Previous studies noted that the risk of suicide is even greater in epilepsy youth with depression, 32 and the prevalence of depression and anxiety in children and adolescents with epilepsy was considered high. 33 Moreover, previous studies reported that young people with epilepsy tended to have poor compliance with antiepileptic treatment and adopt behaviors that could increase their risk of mortality from epilepsy, for example, using alcohol and recreational drugs that may lower their seizure threshold. 34 Alternatively, the high SMR in children and young adults with epilepsy could simply be a reflection of both the low mortality in the reference population and high mortality in patients suffering from epilepsy. 35, 36 We further examined the UCOD for the two boys (<10 years) who died in our study. The two boys died of septicemia (ICD-9: 038) at 5 years old and epilepsy and recurrent seizures (ICD-9: 345) at age of 8, respectively. Based on such small numbers of death and person-years observed in this age category, we were unable to look into the possible causes for the substantially increased SMR in young children. Meanwhile, we could not exclude the possibility that the substantially high SMR noted in young children was due to random variation in risk estimates, represented by a wide confidence interval of SMR. Most studies 1,2,4,6 observed a higher mortality risk in epilepsy males than in their female counterparts. However, compared to the general population of the same gender, our data showed only small difference in sex-specific SMR for adult patients, but still presented some variations in sex-specific SMR for children and young adults albeit the risk estimates were based on very small number of young patients. Given a small sample size for young epilepsy, further interpretation for the potential effect-modification by age on the sex-specific SMR is rather limited. As nearly all studies found lower mortality in patients in the category of unknown etiology (i.e., idiopathic) than in those patients in the remote symptomatic group including progressive CNS disorders such as brain tumors and neurodegenerative disorders, the observed small difference in sex-specific SMR might be attributable to a higher prevalence of certain progressive CNS disorders in males. 37 Further studies are needed to address whether there is an interactive effects of age and sex on the risk of mortality from epilepsy.
Cause-specific SMR
Our study findings are generally consistent with previous findings that people with epilepsy are at greater risks of mortality from cerebrovascular disease (CVD), 2, 3, 6 neoplasm (especially brain cancer), 2,3,6 pneumonia, 2,3 and suicide. [8] [9] [10] Nonetheless, our study also noted an increased risk of mortality from certain specific causes such as liver cancer, heart disease, and some injury related causes, which deserved further comments. One earlier Taiwanese study by Chen et al. of adult patients with epilepsy found that the patients with epilepsy had a 3.5-fold higher risk of death as compared to the general population (SMR: 3.47, 95% CI, 2.46-4.91). 24 Chen et al.'s study also noted that patients with late disease onset (!40 years) had a 4-fold higher risk of death as compared to those with an earlier onset. 24 This earlier study also observed that one-third of the deaths in patients with age-at-onset between 40 and 59 years died of liver cirrhosis and hepatoma. A higher risk of liver cancer noted in our study could be due to the fact that Hepatitis B virus infection is endemic in Taiwan, and this is closely associated with liver cirrhosis and hepatoma. 24 It is not clear by far whether anticonvulsants might contribute to the hepatotoxicity leading to fatal liver disease in patients with epilepsy. 24 Previous studies suggested that intake of antiepileptic drugs (AEDs) might increase the risk of some malignancies, particularly lung cancer, hepatobiliary and pancreatic tumors. However, our study found no increased SMR for lung cancer in patients with epilepsy in Taiwan.
The patients with epilepsy in our sample experienced a 3-fold higher risk of mortality from heart disease, which is rarely reported in the literature. Nilsson et al. followed more than 9000 patients admitted for epilepsy and observed 4001 deaths in the cohort. 7 The excess mortality rate in the cohort was due to a wide range of causes of death, including diseases of the circulatory system with a SMR similar to ours at 3.1 (95% CI, 3.0-3.3). Benn et al. determined underlying cause-specific mortality for incident unprovoked seizures from Northern Manhattan, New York City, and noted that about 25.0% of the death were attributed to heart, second to the proportion of malignant neoplasm (31.3%). 38 A recent
Norwegian study found that both epileptic men and women using carbamazepine (CBZ) had higher total cholesterol, high-density lipoprotein and low-density lipoprotein than controls. They also found that patients with epilepsy recorded less physical activity and lower alcohol use than controls. 39 Further studies are needed to investigate whether medication for treating epilepsy and lifestyle may play certain roles in causing cardiovascular disease in patients with epilepsy.
Apart from a higher risk of suicide death noted in epilepsy, which has been well documented in the literature and has been attributable to a high prevalence of psychiatric comorbidity noted in patients with epilepsy, 10, 40 our study also disclosed a higher SMR for motor vehicle traffic accident, accidental falls and accidental drowning and submersion, with substantially high SMRs (8.0-9.0 fold higher) for the later two causes. It has been reported that people with epilepsy are not injured in traffic accidents more often than are those in the general population, and the traffic accidents happened to epilepsy patients tend to be less severe. 7 A recent study reported that an average of 44,027 US drivers died annually as a result of motor vehicle crashes during 1995-1997; however, only 86 (0.2%, range 82-97) of these deaths were associated with seizures in mortality reports. 21 Unlike those previous studies which provided reassurance for the public policy, adopted in some nations but not in all, of permitting patients whose seizures are controlled to drive, our results suggested caution and imposed certain conditions in issuing driver's licenses. Although people with confirm diagnosis of epilepsy are not allowed by law to possess a driver's license in Taiwan, it is believed that many epilepsy patients are still driving in areas where the public transportation is inadequate. Due to limited information, we were not able to further assess how many patients with epilepsy who died of motor vehicle crashes in our sample truly had their epilepsy satisfactorily controlled. People with epilepsy are thought to be at an increased risk of accidental falls and drowning. 20, 41, 42 Epilepsy associated handicaps and comorbidity and antiepileptic drugs may cause accidents and injuries by impairing cognitive functions and increasing the patient's susceptibility to suffer from the complications of injuries. 41 Petty et al. investigated chronic AED use and physical contributors to falls risk in treated epilepsy patients, and noted that balance performance is impaired in AED users. 42 In a recent meta-analysis, Bell et al. reported that the risk of drowning in people with epilepsy is raised 15-19-fold compared with the general population. 40 This summary relative risk estimate for drowning is much higher than ours (SMR = 8.0). The lower risk estimates for accidental drowning noted in our study patients might reflect lower prevalence of the above risk factors for impaired cognitive functions in patients with epilepsy from southern Taiwan.
Strength and limitations
This study has several methodological strengths. First, our study was based on clinical series of patients from a tertiary hospital, which may provide valid data on the diagnosis of epilepsy. Thus, our study was less likely to incur disease misclassification bias. Second, with a sufficient large size, we were able to make age, sex, and cause specific analyses without comprising the statistical power, which also allowed more specific interpretations of the study findings. Third, we linked our study cohort to the national death registry. This way of doing effectively reduced the likelihood of selection bias resulting from patients' loss to follow-up. Despite the above strengths, several limitations should also be stated. First, the study cohort was consisted only of prevalent cases that sought treatment in hospitals, and was unable to include the patients who did not seek treatments or who died soon after disease onset prior to receiving treatment in the cooperation hospital. It is generally agreed that incident cohort differs from the prevalent cohort in many ways. Prevalent cohorts might underestimate short-term mortality because the more serious cases die in the early phase of the disease and are not included in the calculation of deaths over the period of observation. 43 Our study included prevalent cases, which might under-ascertainment of deaths from epilepsy. Second, our study sample was selected from a tertiary hospital, which might have limited the external validity of the results due to the fact that the patients admitted or cared in medical centers are often highly selected. 14, 44, 45 Third, reliance on death registry in the ascertainment of causes of death may limit our interpretations of study results since the causes of death certified on the death certificate for the deaths of epilepsy patients may not necessarily be epilepsy related. 25 Moreover, because we were not allowed to contact the patients or their family members, or to review patient's medical charts, we were unable to validate the UCOD for the deceased subjects. Despite that, the TDR has been considered accurate and complete, 28 therefore, the potential disease misclassification and under-ascertainment should be minimal; and such disease misclassification is likely to be non-differential, which may lead to under-estimation of effects of epilepsy on mortality, and should not be a valid argument for the significant increased risk of mortality in people with epilepsy observed in this study. Fourth, due to a lack of information on lifestyle, it is not possible for our study to evaluate the roles, if any, of certain risk factors for neoplasm and cerebrovascular disease in causing death in patients with epilepsy. For example, there could be a difference between the smoking habits of people with epilepsy and the general population, and an increased smoking or alcohol intake might be to blame for the increased mortality risk in patients with epilepsy. Fifth, recent studies suggested that the risk of premature death remains significantly elevated at 20-25 years after the index seizure in people with epilepsy, 46 our study was also limited in its length of follow-up. An extension of follow-up period in future studies should be considered to further depict the long-term risk of mortality in people with epilepsy. Last, as an end-point, we used mortality data rather than incidence data. Thus, the concepts of risk and prognosis are mixed.
Conclusions
The SMR of all-cause mortality was significantly increased in patients with epilepsy from southern Taiwan. Such increase in risk was especially noticeable in younger patients, who should be the object of aggressive treatments. Effective measures for preventing mortality from injury related causes should be formatted to further reduce the excess of premature deaths for the patients with epilepsy in Taiwan.
